Health care costs for prostate cancer patients receiving androgen deprivation therapy: Treatment and adverse events

Current Oncology

Volumn 21, Issue 3, 2014, Pages 457-465

  Krahn, M D ^a,b,c,d,e   Bremner, K E ^a,e   Luo, J ^f   Alibhai, S M H ^a,b,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

Adverse events; Androgen deprivation therapy; Cost analysis; Costs; Prostatic neoplasms

Indexed keywords

ANDROGEN;

ACUTE CORONARY SYNDROME; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DEATH; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG COST; FOLLOW UP; FRACTURE; HEALTH CARE COST; HEALTH STATUS; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; ORCHIECTOMY; OSTEOPOROSIS; PROSTATE CANCER; REIMBURSEMENT; VERY ELDERLY;

EID: 84902657937     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1865     Document Type: Article

References (39)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol 2012;13:790-801.
2. Chang SL, Liao JC, Shingal R. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is independent of reimbursement changes: a Medicare and Veterans Health Administration claims analysis. J Urol 2009;182:255-260.
3. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-989.
4. Weight CJ, Klein EA, Jones SJ. Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer 2008;112:2195-21201.
5. Krahn MD, Bremner KE, Tomlinson G, et al. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use? BJU Int 2011;108:1588-1596.
6. Bondy SJ, Iscoe N, Rothwell DM, et al. Trends in hormonal management of prostate cancer: a population-based study in Ontario. Med Care 2001;39:384-396.
7. Shaninian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotrophin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 20 05;103:1615-1624.
8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-244.
9. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Amer 2006;33:181-190.
10. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 2006;60:201-215.
11. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;353:154-164.
12. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410-6417.
13. Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol 2010;184: 918-923.
14. Saylor PJ, Smith MR. Metabolic complications of an-drogen deprivation therapy for prostate cancer. J Urol 2009;181:1998-2006.
15. Alibhai SMH, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009;27:3452-3458.
16. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Institute 2010;102:39-46.
17. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Price Index: Edition 42. Toronto, ON: Queen's Printer for Ontario; 2013. [Available online at: http://www.health.gov.on.ca/en/pro/programs/drugs/ formulary42/edition_42.pdf; cited January 17, 2014]
18. Krupski TL, Foley KA, Baser O, Long S, Macarios D, Li-twin MS. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007;178:1423-1428.
19. Nat ional Collaborating Cancer for Cancer (ncc-c) for the U.K. National Institute for Health and Care Excellence. Prostate Cancer: Diagnosis and Treatment. Cardiff, U.K.: ncc-c; 2008. [Available online at: http://www.nice.org.uk/nicemedia/ live/14348/66232/66232.pdf; cited March 15, 2013]
20. Juurlink DN, Gomes T, Mamdani MM, Gladstone DJ, Kapral MK. The safety of proton pump inhibitors and clopidogrel in patients after stroke. Stroke 2011;42:128-132.
21. Hall S, Schulze K, Groome P, McKillop W, Holowaty E. Using cancer registry data for survival studies: the example of the Ontario Cancer Registry. J Clin Epidemiol 2006;59:67-76.
22. Jacobs P, Yim R. Using Canadian Administrative Databases to Derive Economic Data for Health Technology Assessments. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2009.
23. Bushmeneva K, Nikitovic M, Wodchis PW. Guidelines on Case-Costing Using Administrative Databases in Ontario. Toronto, ON: Health System Performance Research Network; 2011.
24. Godwin M, Seguin R, Wilson R. Queen's University alternative funding plan. Effect on patients, staff, and faculty in the Department of Family Medicine. Can Fam Physician 2000;46:1438-1444.
25. Statistics Canada. Consumer Price Index, health and personal care, by pr ovince (Ontario) [Web pa ge]. Ottaw a, ON: Statistics Canada; n.d. [Most recent version available at: http://www. statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/econ161g-eng.htm; cited October 15, 2013]
26. Statistics Canada. Your Guide to the Consumer Price Index. Cat. no. 62-557-XPB. Ottawa, ON; Statistics Canada; 1996.
27. Reid RJ, MacWilliam L, Verhulst L, Roos N, Atkinson M. Performance of the acg case-mix system in two Canadian provinces. Med Care 2001;39:86-99.
28. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1983; 13322-13328.
29. Asthma Initiative of Michigan. Asthma methods [Web page]. Lansing, MI: Asthma Initiative of Michigan; n.d. [Available at: http://www.getasthmahelp.org/michigan-asthma-statistics-methods.aspx; cited October 15, 2013]
30. Bonzani RA, Stricker HJ, Peabody JO, Menon M. Cost comparison of orchiectomy and leuprolide in metastatic prostate cancer. J Urol 1998;160:2446-2449.
31. Mariani AJ, Glover M, Arita S. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. J Urol 2001;165:104-107.
32. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005;95:59-63.
33. Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer 2010; 116: 5391-5399.
34. Wilson LS, Tesoro, Elkin EP, et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007;109:518-527. [Erratum in: Cancer 2007;109:2155]
35. Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010;152:621-629.
36. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from seer-Medicare data. Med Care 2002;40(suppl 4) 104-117.
37. Krahn MD, Zagorski B, Laporte A, et al. Health care costs associated with prostate cancer: estimates from a population-based study. BJU Int 2010;105:338-346.
38. Seal BS, Asche CV, Puto K, Allen PD. Efficacy, patient-reported outcomes (pros), and tolerability of the changing therapeutic landscape in patients with metastatic prostate cancer (mpc): a systematic literature review. Value Health 2013;16:872-890.
39. Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents. Cancer Treat Rev 2014; 40: 170-177.